文献速递妇产影像技术与安全

靶向新生儿Fc受体:在妊娠中的潜在临床应用

Targeting neonatal Fc receptor: potential clinical applications in pregnancy.
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

本文综述新生儿Fc受体(FcRn)介导IgG经胎盘转运及调节IgG和白蛋白循环半衰期的生物学特性,讨论FcRn阻断剂的开发原理与考虑因素,及其在多种围产期免疫介导疾病中的潜在临床应用。

要点

  • FcRn介导致病性IgG抗体经胎盘转运,可导致胎儿和新生儿细胞与组织损伤。
  • 阻断FcRn可能通过阻止IgG再循环降低母体循环中致病抗体浓度。
  • FcRn阻断剂在围产期免疫介导疾病中具有潜在临床应用价值。

核心结论

  • 阻断FcRn可能是管理围产期免疫介导疾病的有效治疗策略,并可能通过阻止IgG再循环降低母体循环中致病抗体浓度。

研究设计与样本

  • 综述,讨论FcRn生物学、FcRn阻断剂开发的原理与考虑因素及其在围产期免疫介导疾病中的潜在临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The neonatal Fc receptor (FcRn) plays an important role in the transfer of the immunoglobulin G isotype (IgG) from the mother to the fetus. FcRn expressed on endothelial cells also binds to IgG and albumin, regulating the circulating half-lives of these proteins. Alloimmune and autoimmune IgG antibodies have been implicated in various perinatal immune-mediated diseases. FcRn-mediated placental transfer of pathogenic antibodies can result in cell and tissue injury in the fetus and neonate, with devastating outcomes. Thus, blockade of FcRn may be an effective treatment strategy in managing these conditions and could additionally reduce the concentration of pathogenic antibodies in the maternal circulation by preventing IgG recycling. In this review, we discuss the biology of FcRn, the rationale and considerations for development of FcRn-blocking agents, and their potential clinical applications in various perinatal immune-mediated diseases. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Moise KJ, Oepkes D, Lopriore E, et al. Targeting neonatal Fc receptor: potential clinical applications in pregnancy. Ultrasound Obstet Gynecol. 2022. PMID: 35229965. doi:10.1002/uog.24891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。